Alterity Therapeutics: Appendix 4C - Q4 FY22 Quarterly Cash

/PRNewswire/ -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease...

Related Keywords

New Zealand , Australia , United States , United Kingdom , Italy , China , California , Melbourne , Victoria , San Francisco , Italian , Australian , Chinese , American , David Stamler , National Institute Of Health , Nasdaq , Trademark Office , Australian Taxation Office , Italian Medicines Agency , Alterity Therapeutics Limited , Alterity Therapeutics , Zealand Brain Research Institute , Life Sciences Investor Forum , European Commission , Regulatory Agency , Company Healthcare House Call Conference , Global Chinese Financial Forum , American Academy Of Neurology , Securities Exchange , Quarterly Cash Flow Report , Multiple System Atrophy , Australian Government , Brain Research Institute , Agenzia Italiana Del Farmaco , United Kingdom Medicines , Chief Executive Officer David Stamler , Virtual Conference , American Academy , Annual Meeting , System Atrophy , Neurological Disorders , Multiple System Atrophy Fact , Securities Act , Securities Exchange Act , Biotechnology , Health Care Amp Hospitals , Sales Reports ,